Pfizer to buy Hospira for $17 billion
February 5, 2015Sales and Marketing Hospira, Humira, Pfizer, acquisition, biosimilars, merger
Pfizer has struck a deal with Hospira to acquire the company in a deal worth around $17 billion. Industry analysts …
Late-stage successes for Amgen and Roche
February 5, 2015Sales and Marketing Amgen, Bendamustine, Gazyva, Genentech, Humira, Levact, Napp, Roche, adalimumab, obinutuzumab
Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …
GSK blames respiratory woes as sales drop
February 5, 2015Sales and Marketing Advair, GSK, GlaxoSmithKline, HIV, ViiV, Witty, anoro ellipta, breo, lovaza, q4, sales
GlaxoSmithKline’s respiratory business has been flagged as the key factor in the firm’s fourth quarter financial misfortunes, as its total …
Pfizer gets early approval for breast cancer drug
February 4, 2015Sales and Marketing FDA, Pfizer, Xalkori (crizotinib), axitinib, bosulif, bosutinib, femara, ibrance, inlyta, letrozole, palbociclib
The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …
Gilead sales soar on back of hepatitis drugs
February 4, 2015Sales and Marketing Atripla, Gilead, efavirenz, emtricitabine, harvoni, lepidasvir, q4, sofosbuvir, sovaldi, tenofovi
The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 …
Half of UK population will get cancer
February 4, 2015Research and Development, Sales and Marketing CDF, CRUK, Cancer, Jevtana, Sanofi, cabazitaxel
New figures from Cancer Research UK (CRUK) suggest that one in two people will develop cancer at some point in …
Merck releases insomnia drug in US
February 4, 2015Sales and Marketing FDA, Merck, belsomra, insomnia, orexin, suvorexant
Merck’s insomnia drug Belsomra is now available in the US to treat patients who have difficulty falling asleep or staying …
New chairman for Bayer’s Central Works Council
February 4, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Oliver Zühlke, Thomas de Win, central works council
Oliver Zühlke has succeeded Thomas de Win as chairman at the Central Works Council of Bayer as he steps down …
Mylan buys into women’s health
February 3, 2015Sales and Marketing Abbott, FDA, India, Mylan, famy care, female, women
Mylan is to acquire a number of women’s healthcare companies from Indian-based Famy Care that will build upon its 2008 …
Boehringer and Lilly score FDA yes for Glyxambi
February 3, 2015Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin
The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …
Sucampo Pharma names new CFO
February 3, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing andrew smith, sucampo
US firm Sucampo Pharmaceuticals has appointed Andrew Smith from within its ranks to fulfill the role of chief financial officer. …
FDA fast-tracks Roche lung cancer drug
February 2, 2015Sales and Marketing Cancer, FDA, MPDL3280A, Roche, bladder, lung, oncology, pdl1
Roche will be celebrating after its investigational cancer drug MPDL3280A has been fast-tracked by the FDA for the second time. …
Takeda scraps vaccine trial in Phase II
February 2, 2015Research and Development, Sales and Marketing Diptheria-Tetanus-acellular Pertussis (DTaP) and Sabin inactivated poliovirus vaccine (sIPV), Rajeev Venkayya, TAK-361S, Takeda
Takeda has announced it is abandoning the development of a vaccine in Japan that was in Phase II clinical trials.TAK-361S, …
Sun Pharma and Ranbaxy merger gets US nod
February 2, 2015Manufacturing and Production, Sales and Marketing India, Ranbaxy, Sun Pharma, US, generics, merger, recall, torrent
The US Federal Trade Commission has given its approval for Sun Pharma’s $4 billion acquisition of troubled Indian firm Ranbaxy …
Shire drug approved for binge eating disorder
February 2, 2015Sales and Marketing ADHD, FDA, Shire, Vyvanse, binge, eating, lisdexamfetamine dimesylate, obesity
Shire has become the first company to gain FDA approval for a treatment for binge eating disorder (BED) in adults …
Stephen Whitehead: pharma has transformed
February 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, NHS, NICE, PPRS, Stephen Whitehead, lgbt, pharma
According to The Association of the British Pharmaceutical Industry (ABPI) the dominant issue in 2015 will be the affordability and …
Packer Forbes Communications hires director
February 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Packer Forbes, samantha bremner
Samantha Bremner has joined healthcare comms firm Packer Forbes as an associate director and member of the agency’s leadership team.
J&J leukaemia drug gets FDA go-ahead
January 30, 2015Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson
The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …
Government spending on Tamfilu is justified
January 30, 2015Research and Development, Sales and Marketing BMJ, Lancet, Roche, Tamiflu, alltrials, oseltamivir, transparency
The most thorough analysis of Roche’s Tamiflu to date suggests that the controversial treatment can shorten the duration of flu …
Latest content
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
